Pellizzari Christine A 4

What Happened

• Christine A. Pellizzari, a director of Tempest Therapeutics, was granted an award of 1,230 derivative shares on January 27, 2026. The Form 4 reports an acquisition price of $0.00 (no cash paid) and a reported value of $0 for the grant in the filing. This is a compensation award (not a sale) rather than a market purchase.

Key Details

• Transaction date: 2026-01-27; Form 4 filed: 2026-01-28 (timely filing).
• Security type: Derivative award (code A — grant/award/acquisition); reported price $0.00 for 1,230 shares.
• Shares owned after the transaction: not specified in this Form 4 filing.
• Vesting (from footnote): the shares underlying the award will vest in full on the earlier of (i) January 27, 2027 or (ii) the date of the Issuer's 2026 annual stockholder meeting, provided continuous service through that date.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in this filing.

Context

• This filing reflects a compensation grant (likely stock options or RSUs recorded as a derivative award) subject to vesting; the award was not exercised or sold. Such awards are commonly part of director compensation and do not by themselves indicate the director bought or sold stock in the open market.